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In this issue of Chemistry and Biology, Rizvi and colleagues indentify a small molecule that inhibits formin-
mediated actin assembly. Together with recently characterized inhibitors of the Arp2/3 complex (Nolen
et al., 2009) and formins (Gauvin et al., 2009), these small molecules provide useful laboratory tools to dissect
the link between actin nucleators and actin-based structures in living cells.Polymerization of actin filaments initiated
by actin nucleators power a large number
of cellular processes, including morpho-
genesis, the establishment of polarity,
and motility (Pollard and Borisy, 2003).
However, the basic mechanisms that
control and coordinate the action of the
different nucleators in a living cell remain
one of the central questions in cell biology.
Identification of the small molecules that
inhibit selectively these actin nucleators
may help to elucidate their respective,
and even synergistic, role in this complex
biological process.
At the molecular level, de novo nucle-
ation through the action of actin nucle-
ators, such as the well-characterized
formins or the Arp2/3 complex, is the pre-
dominant mechanism that initiates actin
assembly in living cells (Figure 1). Actin
filaments are structurally and thermody-
namically polarized polymers. Although
actin filaments exhibit a fast growing
‘‘barbed’’ end, their spontaneous nucle-
ation is a limiting step. Therefore, actin
nucleators bypass this thermodynami-
cally unfavorable reaction and stimulate
actin assembly (Figure 1). Despite major
progress in understanding their mecha-
nism of action either in vitro or in vivo, it
remains difficult to generate a complete
view of actin nucleator activities and
correlated actin-based structure forma-
tion in metazoan cells. The limitations in
achieving this goal were clearly identified
and discussed in an elegant review by
Chhabra and Higgs (2007). First, routine
imaging techniques for real-time visuali-
zation of the dynamics of actin filaments
within overlapping actin-based structures
are lacking. Second, there is a large
number of nucleator isoforms with func-
tional redundancy. The development of
a super resolution imaging techniquemay help our understanding of the molec-
ular coordination between actin structure
and actin nucleators (Fernandez-Suarez
and Ting, 2008). However, the time reso-
lution of these techniques remains a limi-
tation in studying such a dynamic pro-
cesses as actin assembly. Fortunately, in
yeast, the link between the four different
actin-based structures and their respec-
tive actin nucleators is well characterized
(Moseley and Goode, 2006). Indeed, the
Arp2/3 complex is involved in building
endocytic actin patches, whereas formins
are responsible for contractile ring as-
sembly during division, actin cable
initiation, and the formation of the mating
projection (Moseley and Goode, 2006).
Yeast is therefore an ideal model system
to validate potential small molecules
inhibitors of actin nucleators in vivo that
had been already identified through
in vitro screening assays.
In this issue of Chemistry and Biology,
Rizvi and colleagues (2009) screened the
effect of about 10,000 small molecules
in vitro on the assembly of actin filaments
initiated by formins. Formin inhibitors
were selected for their ability to slow down
formin-mediated actin assembly by at
least 50% at a concentration between
500 and 1000 times higher than the formin
concentration. Similar assay was recently
performed to identify inhibitors of the
Arp2/3 complex (Nolen et al., 2009) and
formins (Gauvin et al., 2009).
The small molecule inhibitor of formin
homology 2 domains (SMIFH2) was found
to satisfy the above criteria. SMIFH2 is
a generic target of formin isoforms from
an evolutionary diverse organism. Formin
family members are characterized by
the presence of two different formin
homology domains (FH1 and FH2) that
modulate the multiple activities of theseChemistry & Biology 16, November 25, 2009proteins on actin assembly (Pruyne et al.,
2002; Sagot et al., 2002). The FH1-FH2
domains are sufficient to account for the
formins nucleation activity, which con-
sists in a processive binding to the actin
filament barbed end and stimulation of
its elongation. The FH2 domain binds
specifically to the barbed end, while
the FH1 domain increases elongation
by recruiting actin monomers from the
medium (Kovar et al., 2006). SMIFH2 likely
interacts with the FH2 domain since it
inhibits both FH2 and FH1FH2 constructs
to the same extent. Additionally, SMIFH2
was found to prevent the interaction of
formin with the barbed ends of actin fila-
ments without affecting the elongation of
filaments at the same end in the absence
of formin. In agreement with its effect on
formin in vitro, low micromolar concentra-
tions of SIMFH2 disrupted all formin-
mediated actin structures in yeast. In the
future, it will be critical to carefully deter-
mine to what extent SMIFH2 interacts
with targets other than formin.
Further progress in understanding the
molecular mechanism of the inhibition of
formins by this compound will require
structural characterization of the com-
plex between the FH2 domain and
SMIFH2. Structural information will be
useful to design better inhibitors with
stronger affinity, formin specificity,or iso-
form selectivity. Interaction of formin at
the barbed ends during actin filament
elongation is a complex mechanism that
small molecules may help to elucidate.
In any case, the characterization of for-
mins or the Arp2/3 complex inhibitors is
a great opportunity for cell biologists to
study their relative effect on actin-based
structure organizations in living cells. We
should all encourage such approaches
because, as these inhibitors will becomeª2009 Elsevier Ltd All rights reserved 1125
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we will have tools to finely
tune cell-dependent actin
processes.
Does This Strategy Have
Pharmacological and
Therapeutic
Implications?
Formin activities seem tightly
correlated with tumor cell
transformation and metas-
tasis. For example, formins
are required for invapodia
formation and invasion of
breast adenocarcinoma cells
(Lizarraga et al., 2009). Rizvi
and colleagues (2009) dem-
onstrated that compounds
targeting formins in animal
cells lead to the disruption
of specific formin-mediated
actin structures. They there-
fore highlight the potential
antiproliferative effect of
SIMFH2 as a result of its
effect on cell division and
motility processes. Although
these major findings validate
formins as a promising target
in anticancer therapies, the
development of antiformin
drugs will have to overcome
standard obstacles as those faced by
any new pharmacological agent, including
cellular uptake, nonspecific interactions,
catabolism, and toxicity. Additionally, for-
min isoform selectivity and potency must
be improved.
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Figure 1. Effect of Inhibition of Actin Nucleators by Small Molecules
Formins and the Arp2/3 complex are actin nucleation factors that promote
actin assembly by bypassing the unfavorable nucleation reaction and/or by
enhancing the rate of monomer association at the fast growing barbed end.
The Arp2/3 complex catalyzes the formation of branched actin filaments, while
formins generate long unbranched actin filaments. Interestingly, the small
molecules SMIFH2 (Rizvi et al., 2009) and the CK-666 (Nolen et al., 2009)
inhibit specifically these two actin nucleators. In vivo, these small molecules
are important tools to correlate actin nucleator activities and actin-based
structure formation (B, barbed end; P, pointed end). Recently, other formin
inhibitors have been characterized but not tested in live cells (Gauvin et al.,
2009).1126 Chemistry & Biology 16, November 25, 2009 ª2009 Elsevier Ltd All rights reserved
